多発性骨髄腫市場 - KOLの考察

当レポートでは、多発性骨髄腫市場について調査分析し、上市済みの治療法とパイプラインにある治療法に対するKOLの考察を提供しています。

目次

エグゼクティブサマリー

現在と将来の治療アルゴリズム

調査目的

モノクローナル抗体（mAb）

• 承認済みの医薬品
  • Darzalex (daratumumab; Janssen)
  • Sarclisa (isatuximab; Sanofi)
• パイプライン医薬品
  • Modakafusp alfa (TAK-573; Takeda)

免疫調節薬（IMiDs）

• パイプライン医薬品
  • Iberdomide (CC-220; BMS) and mezigdomide (CC-92480; BMS)

アポトーシス刺激剤

• パイプライン医薬品
  • Venetoclax (Venclexta/Venclyxto; AbbVie/Genentech)

CAR T細胞療法

• 承認済みの治療法
  • Abecma (idecabtagene vicleucel; BMS/2seventy bio)
  • Carvykti (ciltacabtagene autoleucel; Janssen/Legend Biotech)
• パイプライン治療法
  • 新しいCAR T細胞療法（Gilead [Kite]/Arcellx's CART-ddBCMA; BMS' BMS-986393）

二重特異性抗体

• 承認済みの医薬品
  • Tecvayli (teclistamab; Janssen)
• パイプライン医薬品
  • BMCAを標的とする二重特異性抗体（Pfizer's elranatamab; Regeneron's linvoseltamab; AbbVie's ABBV-383）
  • 新しい標的を持つ二重特異性抗体（Janssen's talquetamab; Roche's cevostamab）

将来の治療動向

• 重要な考察のまとめ

付録

KOLの速報

In which frontline settings is Janssen's widely-used anti-CD38 mAb Darzalex expanding and what factors could increase the prospects of Sanofi's competitor Sarclisa? CAR-T cell therapies such as Janssen's Carvykti may be achieving unprecedented response rates but are hampered by concerns about durability and access. How might readily available bispecific antibody Tecvayli capitalise? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users can access the following KOL Bulletins via the Attachments area.

• 31 Aug 2023 KOL Bulletin -- Leading MM specialist discusses outlook for new bispecifics from J&J, Pfizer

Table of Contents

Executive summary

Current and future treatment algorithm

Research objectives

Monoclonal antibodies (mAbs)

• Approved drugs
  • Darzalex (daratumumab; Janssen)
  • Sarclisa (isatuximab; Sanofi)
• Pipeline drugs
  • Modakafusp alfa (TAK-573; Takeda)

Immunomodulatory drugs (IMiDs)

• Pipeline drugs
  • Iberdomide (CC-220; BMS) and mezigdomide (CC-92480; BMS)

Apoptosis stimulants

• Pipeline drugs
  • Venetoclax (Venclexta/Venclyxto; AbbVie/Genentech)

CAR T-cell therapies

• Approved therapies
  • Abecma (idecabtagene vicleucel; BMS/2seventy bio)
  • Carvykti (ciltacabtagene autoleucel; Janssen/Legend Biotech)
• Pipeline therapies
  • Novel CAR T-cell therapies (Gilead [Kite]/Arcellx's CART-ddBCMA; BMS' BMS-986393)

Bispecific antibodies

• Approved drugs
  • Tecvayli (teclistamab; Janssen)
• Pipeline drugs
  • BMCA-targeting bispecific antibodies (Pfizer's elranatamab; Regeneron's linvoseltamab; AbbVie's ABBV-383)
  • Bispecific antibodies with novel targets (Janssen's talquetamab; Roche's cevostamab)

Future treatment trends

• Key insights summary

Appendix

• KOL details
  • KOLs from the USA
  • KOLs from Europe

KOL Bulletins